Navigation Links
Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Date:5/7/2009

NEW HAVEN, Conn., May 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that researchers will be presenting two presentations and two posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Helsinki, Finland from May 16-19, 2009.

Independent researchers, Dr. Franciose van Bambeke and Dr. Sandrine Lemaire, both from Universite Catholique de Louvain, will each make oral presentations describing the unique microbiological and pharmacodynamic properties of Rib-X's novel oxazolidinone, radezolid, during a session entitled Pharmacokinetics/Pharmacodynamics: Clinical Relevance, on Saturday, May 16th.

Additionally, Rib-X researchers will be presenting two posters on delafloxacin, one of which discusses the activity and efficacy of delafloxacin in a Phase 2 clinical trial for complicated Skin and Skin Structure Infections. The second poster session details the in vitro activity of delafloxacin against a large, worldwide panel of methicillin-resistant Staphylococcus aureus.

    Details on the presentations and abstracts are as follows:

     Date        Time    Session          Title                Location/Poster

    May 16,    3:06pm -   PK/PD:     The novel oxazolidinone   Lecture Hall 3a
     2009      3:18pm     Clinical   radezolid (RX-1741)
                          Relevance  accumulates in THP-1
                                     macrophages: comparative
                                     studies with linezolid
                                     and azithromycin.

    May 16,    3:18pm -   PK/PD:     Radezolid (RX-1741), a    Lecture Hall 3a
     2009      3:30pm     Clinical   novel oxazolidinone, is
                          Relev
'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
2. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
3. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
4. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
10. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
11. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Sunnyvale, CA (PRWEB) July 22, 2014 ... begin on September 9th, 2014 and will comprise of ... and Application’ classes. The TechTrainings is a series of ... professionals, designed to help them reach the next step ... SAS class is taught by Jennifer Kang, Senior ...
(Date:7/21/2014)... Vernon Hills, IL (PRWEB) July 21, 2014 ... remote control, and simple programming, the new ... Pump Head is easy to operate for ... between cycles for hands-free dispensing. The batch count ... the cumulative volume or totalizer tracks amount dispensed ...
(Date:7/21/2014)... yield so far is small, but chemists at the ... substitution process to make a precursor to transparent thin ... energy devices. , A paper describing the approach is ... of the journal Inorganic Chemistry , which draws ... nuclear chemistry fields. The paper was chosen by the ...
(Date:7/21/2014)... Sleep disturbances such as insomnia, hypersomnia, ... depression. According to a study published by the ... of depressed patients have insomnia symptoms, and hypersomnia ... adults and 10% of older patients, with a ... have a major impact on quality of life, ...
Breaking Biology Technology:Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Oregon chemists eye improved thin films with metal substitution 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3
... April 21 Startech,Environmental Corp. (OTC Bulletin ... Energy Company, announced today that the,EnviroSafe Industrial ... has,expanded its original plans for its new ... intention to install three Plasma Converters Systems,purchased ...
... joins Connecticut office to Focus on Specialty ... Pharmaceuticals, Drug Delivery and Biotechnology, STAMFORD, Conn., April ... venture capital firm that invests in life science and,medical ... joined as an Entrepreneur-in-Residence in the firm,s Connecticut,office. Most ...
... VANCOUVER, April 21 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... pharmaceutical and,medical device company, today announced that it ... EU human clinical trials for its Vascular Wrap,product ... a safety review to evaluate an imbalance of ...
Cached Biology Technology:Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 2Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico 3David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence 2Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 2Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 3Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials 4
(Date:7/22/2014)... study that examined the survival rates of 12 ... commercial longline fishing operations found large differences in ... dusky, and scalloped hammerhead being the most,vulnerable. The ... Miami (UM) Rosenstiel School of,Marine and Atmospheric Science ... Policy, provides,new information to consider for future conservation ...
(Date:7/22/2014)... uncanny precision are key parts of high-powered lenses, ... instead of electricity. But producing these crystals by ... precise beam of electrons, is often extremely difficult ... Columbia universities have proposed a new method that ... specialized materials, known as photonic crystals, with relative ...
(Date:7/22/2014)... most kids will hear that drinking milk helps make their bones ... these messages foster the idea that if something is good for ... in the Journal of Consumer Research , when children hear ... it. , "We predicted that when food is presented to children ... goal such as learning how to read or count, they would ...
Breaking Biology News(10 mins):New study reveals vulnerability of sharks as collateral damage in commercial fishing 2Technique simplifies the creation of high-tech crystals 2Technique simplifies the creation of high-tech crystals 3
... Researchers at Delft University of Technology and the ... provides a unique test and measurement platform for the ... the journal Nature Nanotechnology (June 19 - ... with key proteins which mimicks the natural nuclear pore. ...
... pointed to a collection of test tubes in her Iowa ... like they were holding very weak coffee. That meant microorganisms ... biochemically converting sugars into hydrocarbons, said Jarboe, an Iowa State ... of the sugars in those test tubes were produced by ...
... prolonged snowfall can bring about unexpected conditions that encourage fungal ... according to experts. A new international study confirms that ... grow bigger, heavy and prolonged snow can, in certain circumstances, ... strains. The research results, published in the journal ...
Cached Biology News:Mimicking nature at the nanoscale: Selective transport across a biomimetic nanopore 2Iowa State hybrid lab combines technologies to make biorenewable fuels and products 2Iowa State hybrid lab combines technologies to make biorenewable fuels and products 3Arctic snow harbors deadly assassin 2
DNA Repair Sampler Kit 10g each...
PKC Sampler Kit 10 mu g each...
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
Tumor Suppressor Sampler Kit 10 mu g each...
Biology Products: